BeOne Medicines AG (HKG:6160)
225.00
+9.40 (4.36%)
Oct 16, 2026, 4:08 PM HKT
BeOne Medicines AG Employees
BeOne Medicines AG had 12,000 employees as of June 30, 2026. The number of employees increased by 1,000 or 9.09% compared to the same quarter last year. That makes BeOne Medicines AG the 2,877th largest employer in the world and 248th in Hong Kong.
Employees
12,000
Change
1,000
Growth
9.09%
Revenue / Employee
4.01M HKD
Profits / Employee
428.51K HKD
Market Cap
329.32B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Mar 31, 2026 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Dec 31, 2025 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Sep 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Jun 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Mar 31, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 11,000 | 0 |
| Jun 30, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Mar 31, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 10,600 | 0 |
| Mar 31, 2023 | 9,400 | 1,100 | 13.25% | 9,400 | 0 |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 9,000 | 0 |
| Sep 30, 2022 | 9,000 | 1,400 | 18.42% | 9,000 | 0 |
| Mar 31, 2022 | 8,300 | 2,900 | 53.70% | 8,300 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| Innovent Biologics | 8,754 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
BeOne Medicines AG News
- 4 hours ago - BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 - Business Wire
- 3 days ago - BeOne Medicines price target raised to $425 from $405 at Morgan Stanley - TheFly
- 8 days ago - BeOne Medicines (TSE:4579) -- Revenue Growth and Market Leadership | Baird Funds Q3 2026 - GuruFocus
- 11 days ago - BeOne Medicines price target raised to $459 from $450 at RBC Capital - TheFly
- 12 days ago - BeOne Medicines price target raised to $420 from $418 at Truist - TheFly
- 16 days ago - BeOne Medicines Ltd (ONC) Insider Sale: SVP, General Counsel Chan Lee Sells 1,115 Shares - GuruFocus
- 17 days ago - Biotech Leader BeOne Medicines Poised To Hit Early Buy Points - Investor's Business Daily
- 17 days ago - BeOne Medicines price target raised to $445 from $425 at JPMorgan - TheFly